Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Microgen in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 367.50.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Microgen. This N/A consensus rating has held steady for over two years.
Microgen plc, together with its subsidiaries, develops, implements, and supports business critical software and related services in the United Kingdom and internationally. It operates through two segments, Aptitude Software and Microgen Financial Systems. The Aptitude Software segment provides a suite of specialized finance management software applications for banking, healthcare, insurance, and telecommunications customers. Its applications include Aptitude Insurance Calculation Engine that focuses on insurance contracts; Aptitude Lease Accounting Engine, which addresses leasing standards; Aptitude Revenue Recognition Engine for revenue recognition requirements; Aptitude RevStream, a cloud-enabled revenue management software; Aptitude Accounting Hub that transforms financial, management, and statutory accounting; and Aptitude Allocation Engine that offers interfaces to set-up and apply rules to allocate cost and revenue. This segment licenses its software; and provides software maintenance/support, software subscriptions for its cloud-based offerings; and implementation services. The Microgen Financial Systems segment offers Microgen 5Series, a wealth management software for both on-shore and off-shore markets; and Microgen Bacway, a suite of payments software products. It also provides maintenance, support, and development services on a range of software products and applications developed by third parties. Microgen plc was founded in 1974 and is headquartered in London, the United Kingdom.